Updated Guidance for Using Intravenous Artesunate to Treat Severe Malaria in the United States
In the United States, about 2,000 cases of malaria are imported each year, 300 of which are severe. There is no FDA-approved drug available to treat severe malaria. Intravenous (IV) artesunate, which is neither FDA-approved nor commercially available, is currently the first-line drug to treat severe malaria in the United States. Since April 1, 2019, all U.S. clinicians must call the CDC to obtain IV artesunate to treat cases of severe malaria.
During this COCA Call, clinicians will learn about CDC’s updated guidance for using IV artesunate—a life-saving drug—to treat patients with severe malaria in the United States, and will receive an update on CDC’s artesunate program.
Date: Tuesday, December 10, 2019
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-121019—(Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Updated Guidance for Using Intravenous Artesunate to Treat Severe Malaria in the United States” Tuesday, December 10, 2019, please visit TCEO and follow these 9 Simple Steps by January 13, 2020.
To receive continuing education (CE) for WD2922-121019—(Web on demand) Clinician Outreach and Communication Activity (COCA) Calls/Webinars “Updated Guidance for Using Intravenous Artesunate to Treat Severe Malaria in the United States” Tuesday, December 10, 2019, please visit TCEO and follow these 9 Simple Steps by January 14, 2022.
At the conclusion of the session, the participant will be able to accomplish the following:
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of health care providers.
Activity Specific Objectives
- Identify the criteria for severe malaria.
- Describe how to obtain IV artesunate from CDC.
- Explain the treatment of severe malaria, including interim treatment and the use of IV artesunate.
- Discuss the impact of the National Artesunate for Severe Malaria Program on the treatment of severe malaria in the United States.
Slides: View Slides pdf icon[PDF – 2 MB]
Kathrine R. Tan, MD, MPH
Chief, Domestic Response Unit, Malaria Branch
Division of Parasitic Diseases and Malaria
Center for Global Health
Centers for Disease Control and Prevention
Clive Brown, MBBS, MPH, MSc, DTM&H
Chief, Quarantine and Border Health Services Branch
Division of Global Migration and Quarantine
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
A few minutes before the webinar begins on Tuesday, December 10, 2019, please click the link below to join the webinar:https://zoom.us/j/583153296external icon
Or iPhone one-tap:
US: +16468769923,,583153296# or +16699006833,,583153296#
Dial(for higher quality, dial a number based on your current location):
US: +1 646 876 9923 or +1 669 900 6833
Webinar ID: 583 153 296
International numbers available: https://zoom.us/u/anixAVglVexternal icon
Malaria Treatment (United States)
Intravenous Artesunate for Treatment of Severe Malaria in the United States
WC2922 0387-0000-19-178-L04-P (must be completed by 1/13/2020)
WD2922 0387-0000-19-178-H04-P (must be completed by 01/14/2022)
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:email@example.com
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.
- Fees: Continuing Education (CE) is free.
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-19-178-L04-P and enduring 0387-0000-19-178-H04-P course category.
This activity has been designated as Knowledge-Based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
For Certified Public Health Professionals (CPH)
The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Tan’s discussion of intravenous (IV) antimalarial as there is no FDA-approved, commercially available intravenous (IV) antimalarial for the treatment of severe malaria in the United States. IV artesunate, the first-line drug for treatment of severe malaria in the United States, is not FDA approved but is available through CDC under an expanded use investigational new drug (IND) protocol. IV artesunate is the only option in the United States for treatment of severe malaria.
CDC did not accept commercial support for this continuing education activity.